306297-00-7

Upstream product

• 75-16-1 methylmagnesium bromide 
• 306296-99-1 4-Cyano-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidine-1-carboxylic acid tert-butyl ester 
• 306296-78-6 tert-butyl-4-methyl-4-[(3S)-3-methylpiperazin-1-yl]piperidine-1-carboxylate 
• 709-63-7 1-(4-trifluoromethylphenyl)ethanone 
• 74879-18-8 (S)-2-methylpiperazine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 147081-29-6 (S)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 306296-87-7 1-[4(trifluoromethyl)-α(S)-methylbenzyl]-2(S)-methyl-4-(tert-butoxycarbonyl)piperazine 
• 306296-89-9 (S)-2-Methyl-1-[(S)-1-(4-trifluoromethyl-phenyl)-ethyl]-piperazine 
• 1737-26-4 (R)-1-[4-(trifluoromethyl)phenyl]ethan-1-ol 
• 306296-86-6 [(1R)-1-[4-(trifluoromethyl)phenyl]ethyl] methanesulfonate 

Downstream Products

• 544704-12-3 2-methyl-4-(4-methylpiperidin-4-yl)-1-[1-(4-trifluoromethylphenyl)ethyl]piperazine 
• 306293-36-7 Sch 350581 
• 306293-41-4 Sch 350634 

Relevant academic research and scientific papers

Forward- and reverse-synthesis of piperazinopiperidine amide analogs: A general access to structurally diverse 4-piperazinopiperidine-based CCR5 antagonists

Piperazinopiperidine amide analogs are among the most promising CCR5 antagonists. As an effective extension of a previously-reported methodology to synthesize such compounds, forward- and reverse-syntheses were successfully developed in which the convergent synthesis of the piperazinopiperidine nucleus, with a building block of 4-substituent-4-aminopiperidine, served as a common key step. The two-way approach affords a comprehensive access to the piperazinopiperidine templated library with variation on the pharmacophore sites. Thus, a SAR study of our synthesized piperazinopiperidine-based CCR5 antagonists was conducted with respect to the structure and configuration of the substituent on the piperazine ring. The S-configuration of the benzylic-substituent is vital for the CCR5 binding, and the bulky or aryl substituent on the 2-position in the piperazine ring is detrimental to the activity. By using the forward-synthesis approach, the best compound in the chiral piperazine-based CCR5 antagonist series, Sch-D (Vicriviroc), was conveniently synthesized in an excellent yield. The Royal Society of Chemistry.

PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS

The use is described of CCR5 antagonists of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R 1 is hydrogen or alkyl; R 2 is substituted phenyl, substituted heteroary

Piperazine derivatives useful as CCR5 antagonists

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1is hydrogen or alkyl; R2is substituted phenyl, substituted heter

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4methyl-4-[3(S)-methyl-4-[1(S)-[4- (trifluoromethyl) phenyl]ethyl]-1-piperazinyl]piperidine N1-oxide (Sch-350634), an orally bioavailable, poten

Truncation of the original piperidino-2(S)-methyl piperazine lead structure 2, from a family of muscarinic antagonists, gave compound 8 which has improved selectivity for the HIV-1 co-receptor CCR5 over muscarinic receptors. Further optimization for pharm